In HD patients, the MIS is associated with inflammation, nutritional status, quality of
life, and 5-year prospective mortality. The mortality predictability of the MIS appears equal to serum
interleukin 6 and somewhat greater than C-reactive protein levels. Controlled trials are warranted to
examine whether interventions to improve the MIS can also improve clinical outcomes in HD patients.
Am J Kidney Dis 53:298-309. © 2009 by the National Kidney Foundation, Inc.